Evaluation of a Vaccine Candidate Designed for Broad-Spectrum Protection against Type A Foot-and-Mouth Disease in Asia
Sung Ho Shin,
Seong Yun Hwang,
Hyun-Mi Kim,
Se Hee Shin,
Mi-Kyeong Ko,
Min Ja Lee,
Su-Mi Kim,
Jong-Hyeon Park
Affiliations
Sung Ho Shin
Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon City 39660, Gyeongsangbuk-do, Republic of Korea
Seong Yun Hwang
Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon City 39660, Gyeongsangbuk-do, Republic of Korea
Hyun-Mi Kim
Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon City 39660, Gyeongsangbuk-do, Republic of Korea
Se Hee Shin
VAXDIGM, Room 335, 3rd Floor, 11, Bongeunsa-ro 63-gil, Gangnam-gu, Seoul 060097, Republic of Korea
Mi-Kyeong Ko
Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon City 39660, Gyeongsangbuk-do, Republic of Korea
Min Ja Lee
Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon City 39660, Gyeongsangbuk-do, Republic of Korea
Su-Mi Kim
Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon City 39660, Gyeongsangbuk-do, Republic of Korea
Jong-Hyeon Park
Center for Foot-and-Mouth Disease Vaccine Research, Animal and Plant Quarantine Agency, 177 Hyeoksin 8-ro, Gimcheon City 39660, Gyeongsangbuk-do, Republic of Korea
Foot-and-mouth disease (FMD) vaccines are currently the most powerful protective and preventive measures used to control FMD. In this study, the chimeric vaccine strain containing antigenic epitopes from the FMD virus serotype A, which belongs to the ASIA topotype, was produced and evaluated. The chimeric vaccine strains contain sea-97/G1 (VP4, VP2, VP3) and A22 Iraq (VP1) or G-VII (VP1) for use in FMD vaccines in Asia. The 50% protective dose was determined in mice. Vaccinated mice were challenged with three different type A viruses (Sea-97/G1, Sea-97/G2, G-VII clade) seven days post-vaccination (dpv), and mice that received the vaccine candidates were protected against the three viruses. The protective capability of one of the vaccine candidates was evaluated in pigs. Vaccinated pigs were challenged with three different type A viruses (Sea-97/G1, Sea-97/G2, G-VII clade) at 28 dpv, and pigs that received the vaccine candidate were protected against the three viruses. The results showed that this vaccine candidate, which was designed to provide protection against FMD in Asia, efficiently protected pigs against virus challenge and thus has potential as a broad-spectrum vaccine for various epidemic FMD viruses.
